IPHA

Innate Pharma S.A.

2.57 USD
+0.55 (+27.23%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Innate Pharma S.A. stock is down -11.38% since 30 days ago. The next earnings date is Sep 12, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 60% of the previous 4 June’s closed higher than May. 100% of analysts rate it a buy.

About Innate Pharma S.A.

Innate Pharma S.A. discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the. treatment of cutaneous T-cell and peripheral T-Cell lymphoma. Its products include Monalizumab, an immune checkpoint inhibitor that is in. Phase III clinical trial to treat colorectal and lung cancer.